fingolimod hydrochloride has been researched along with Crohn Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Haens, G; Danese, S; Davies, M; Hibi, T; Watanabe, M | 1 |
| Benson, EL; Heuvelman, DM; Masferrer, JL; Radi, ZA | 1 |
1 trial(s) available for fingolimod hydrochloride and Crohn Disease
| Article | Year |
|---|---|
A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease.
Topics: Crohn Disease; Double-Blind Method; Fingolimod Hydrochloride; Humans; Propanolamines; Treatment Outcome | 2022 |
1 other study(ies) available for fingolimod hydrochloride and Crohn Disease
| Article | Year |
|---|---|
Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model.
Topics: Animals; Antibodies, Monoclonal; Crohn Disease; Diarrhea; Disease Models, Animal; Female; Fingolimod Hydrochloride; Gastrointestinal Agents; Interleukin-12; Interleukin-23; Mice; Mice, Inbred BALB C; Organ Size; Propylene Glycols; Sphingosine; Sulfasalazine; Trinitrobenzenesulfonic Acid; Weight Loss | 2011 |